Neal Shore, MD on Darolutamide VS. Apalutamide and Enzalutamide in nmCRPC #ASCO2020 @UNCurology

Neal Shore, MD on Darolutamide VS. Apalutamide and Enzalutamide in nmCRPC #ASCO2020 @UNCurology

User Photo
Cancer-News

1 month
10 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): MAIC.

Read here: https://meetinglibrary.asco.org/record/188306/abstract

Up Next Autoplay
User Photo